Indeed, the use of the pan-PI3K inhibitors LY-294002, PX-866, BKM-120, GDC-0941 and NVP-BEZ235 triggers an AKT reactivation after transient inhibition in colorectal tumor cells [7] or in pancreatic cancer cell lines [8]. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.